Review
Version 1
This version is not peer-reviewed
HPV-Related Cancer Vaccine Strategies: A Focus on China
Version 1
: Received: 11 October 2024 / Approved: 14 October 2024 / Online: 15 October 2024 (11:45:38 CEST)
How to cite: Cai, X.; Xu, L. HPV-Related Cancer Vaccine Strategies: A Focus on China. Preprints 2024, 2024101013. https://doi.org/10.20944/preprints202410.1013.v1 Cai, X.; Xu, L. HPV-Related Cancer Vaccine Strategies: A Focus on China. Preprints 2024, 2024101013. https://doi.org/10.20944/preprints202410.1013.v1
Abstract
Human papillomavirus (HPV) persistent infection is a major pathogenic factor for HPV-related cancers, such as cervical cancer (CC), vaginal cancer, vulvar cancer, anal cancer, penile cancer, and head and neck cancer (HNC). Vaccination against HPV is an effective measure to block the transmission of the virus and to prevent HPV infections and the occurrence of related cancers. Since the introduction of the world’s first prophylactic HPV vaccine, there has been a decline in the incidence of HPV infections and associated cancers. Furthermore, there are currently ongoing developments of preventive vaccines that cover more HPV types, as well as the clinical application of therapeutic HPV vaccines. This article reviews the latest literature on the research progress, efficacy, and safety of HPV vaccines for these cancers, providing a reference for HPV vaccination strategy.
Keywords
HPV; Vaccine; Genital system; Head and neck cancer
Subject
Medicine and Pharmacology, Obstetrics and Gynaecology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
